Inhibitory Antibodies

A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.

The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.

After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.

Targetmol provides xnum monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.

Cat. No.	Product name	CAS No.	Purity	Chemical Structure
T77408	Abagovomab	792921-10-9	98%	Abagovomab
T77408	Abagovomab (Anti-Human CA-125 Recombinant Antibody) is a murine monoclonal antibody that targets the tumor-associated antigen CA-125. Abagovomab is produced by h...			Abagovomab
T77412	Lupartumab	1640971-88-5	98%	Lupartumab
T77412	Lupartumab (BAY 1112623) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used to synthesize antibody-active molecular couplers that can be used to study...			Lupartumab
T77415	Ladiratuzumab	1629760-28-6	98%	Ladiratuzumab
T77415	LadiratuzumAb (hLIV22) is a humanized monoclonal antibody targeting LIV-1/ZIP6.LadiratuzumAb is a naked antibody to SGN-LIV1A and is capable of synthesizing an a...			Ladiratuzumab
T77416	Opicinumab	1422268-07-2	98%	Opicinumab
T77416	Opicinumab (BIIB033) is a novel monoclonal antibody against LINGO-1 that may be used to prevent and delay acute optic neuritis and recurrent multiple sclerosis.			Opicinumab
T77422	Lacutamab	2187368-16-5	98%	Lacutamab
T77422	Lacutamab (IPH 4102) is a potent and selective humanized anti-KIR3DL2 antibody.Lacutamab has potential anticancer activity for the study of leukemia and lymphoma...			Lacutamab
T77423	Lirilumab	1000676-41-4	98%	Lirilumab
T77423	Lirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical c...			Lirilumab
T77426	Pascolizumab	331243-22-2	98%	Pascolizumab
T77426	Pascolizumab (SB-240683) is a humanized monoclonal antibody against IL-4. Pascolizumab has asthmatic effects and can be used to study allergic rhinitis.			Pascolizumab
T77432	Anifrolumab	1326232-46-5	98%	Anifrolumab
T77432	Anifrolumab（MEDI-546） is a potent type I interferon (IFN) receptor antagonist, a human monoclonal antibody that targets IFN.Anifrolumab inhibits the activity of ...			Anifrolumab
T77433	Feladilimab	2252518-85-5	98%	Feladilimab
T77433	Feladilimab (GSK3359609) is an IgG4 monoclonal antibody that is an ICOS agonist. Feladilimab binds to ICOS-expressing T cells, induces IFNγ, and increases PD-1/L...			Feladilimab
T77434	Vopratelimab	2039148-04-2	98%	Vopratelimab
T77434	Vopratelimab (JTX-2011) is a selective humanized immunoglobulin G1-kappa monoclonal antibody that is a potent ICOS agonist. Vopratelimab has a high affinity for ...			Vopratelimab
T77439	Glembatumumab	1020264-78-1	98%	Glembatumumab
T77439	Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma.Glem...			Glembatumumab
T77440	Codrituzumab	1365267-33-9	98%	Codrituzumab
T77440	Codrituzumab (GC3) is a humanized antibody against the glypican-3 hepatocellular carcinoma protein that can be used in combination with sorafenib to study incura...			Codrituzumab
T77442	Glenzocimab	2101829-58-5	98%	Glenzocimab
T77442	Glenzocimab (ACT017) is a Fab fragment of a humanized anti-GPVI monoclonal antibody. Glenzocimab demonstrated inhibition of collagen-induced platelet aggregation...			Glenzocimab
T77443	Racotumomab	946832-34-4	98%	Racotumomab
T77443	Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is a mouse γ-type anti-recombinant antibody. It can specifically induce an antibody response against Neu-gly...			Racotumomab
T77445	Apitegromab	2278276-46-1	98%	Apitegromab
T77445	Apitegromab (SRK-015) is a new myostatin inhibitor, an antibody targeting myostatin precursor, which can be used to study neuromuscular diseases including spinal...			Apitegromab
T77448	Naxitamab	1879925-92-4	98%	Naxitamab
T77448	Naxitamab (Hu3F8) is a humanized monoclonal antibody against GD2 (hu3F8). Naxitamab has antitumor activity and can be used to study neuroblastoma, osteosarcoma, ...			Naxitamab
T77455	Burosumab	1610833-03-8	98%
T77455	Burosumab(KRN23) is a human monoclonal antibody targeting fibroblast growth factor 23 (FGF23) for the treatment of cutaneous-skeletal hypophosphatemic syndrome (...
T77456	Lumiliximab	357613-86-6	98%	Lumiliximab
T77456	Lumiliximab (IDEC-152) is a primate-ized chimeric antibody targeting CD23 rhesus monkey/human chimeric antibody with inhibitory effects on IgE antibody productio...			Lumiliximab
T77466	Tremelimumab	745013-59-6	98%
T77466	Tremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatm...
T77471	Tinurilimab	2226224-30-0	98%	Tinurilimab
T77471	Tinurilimab (Bay 1834942) is a monoclonal antibody that targets and inhibits CEACAM6, an immune checkpoint regulator. Tinurilimab can be used in studies about ef...			Tinurilimab